Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Lymphangioleiomyomatosis.

Doubková M, Štefániková M, Čan V, Merta Z, Svoboda M.

Klin Onkol. 2019 Fall;32(5):367-374. doi: 10.14735/amko2019367.

PMID:
31610670
2.

MicroRNA Biogenesis Pathway Genes Are Deregulated in Colorectal Cancer.

Vychytilova-Faltejskova P, Svobodova Kovarikova A, Grolich T, Prochazka V, Slaba K, Machackova T, Halamkova J, Svoboda M, Kala Z, Kiss I, Slaby O.

Int J Mol Sci. 2019 Sep 10;20(18). pii: E4460. doi: 10.3390/ijms20184460.

3.

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients.

Kovacova J, Juracek J, Poprach A, Kopecky J, Fiala O, Svoboda M, Fabian P, Radova L, Brabec P, Buchler T, Slaby O.

Cancer Genomics Proteomics. 2019 Sep-Oct;16(5):353-359. doi: 10.21873/cgp.20140.

4.

Methods of Classical and Molecular Cytogenetics Suitable for Biodosimetry of Persons with Professional Exposure to Carcinogens.

Petrovová M, Svoboda M.

Klin Onkol. 2019 Summer;32(4):270-276. doi: 10.14735/amko2019270.

PMID:
31426642
5.

BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.

Foretová L, Navrátilová M, Svoboda M, Házová J, Vašíčková P, Sťahlová EH, Fabian P, Schneiderová M, Macháčková E.

Klin Onkol. 2019 Summer;32(Supplementum2):118-122. doi: 10.14735/amko2019S118.

PMID:
31409087
6.

GAPPS - Gastric Adenocarcinoma and Proximal Polyposis of the Stomach Syndrome in 8 Families Tested at Masaryk Memorial Cancer Institute - Prevention and Prophylactic Gastrectomies.

Foretová L, Navrátilová M, Svoboda M, Grell P, Nemec L, Sirotek L, Obermannová R, Novotný I, Sachlova M, Fabian P, Kroupa R, Vasickova P, Házová J, Sťahlová EH, Machackova E.

Klin Onkol. 2019 Summer;32(Supplementum2):109-117. doi: 10.14735/amko2019S109.

PMID:
31409086
7.

Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.

Machackova E, Claes K, Mikova M, Házová J, Sťahlová EH, Vasickova P, Trbusek M, Navrátilová M, Svoboda M, Foretová L.

Klin Onkol. 2019 Summer;32(Supplementum2):51-71. doi: 10.14735/amko2019S51. Review.

PMID:
31409081
8.

Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.

Foretová L, Navrátilová M, Svoboda M, Vašíčková P, Sťahlová EH, Házová J, Kleiblová P, Kleibl Z, Macháčková E, Palácová M, Petráková K.

Klin Onkol. 2019 Summer;32(Supplementum2):6-13. doi: 10.14735/amko2019S6. Review.

PMID:
31409076
9.

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis.

Buchler T, Chloupkova R, Poprach A, Fiala O, Kiss I, Kopeckova K, Dusek L, Veskrnova V, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Melichar B.

Cancer Manag Res. 2018 Dec 28;11:359-368. doi: 10.2147/CMAR.S183093. eCollection 2019.

10.

Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.

Juracek J, Stanik M, Vesela P, Radova L, Dolezel J, Svoboda M, Slaby O.

Urol Oncol. 2019 Mar;37(3):184.e1-184.e7. doi: 10.1016/j.urolonc.2018.10.014. Epub 2018 Nov 13.

PMID:
30446443
11.

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis.

Fiala O, Veskrnova V, Chloupkova R, Poprach A, Kiss I, Kopeckova K, Dusek L, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Boubliková L, Dvorak J, Melichar B, Buchler T.

Target Oncol. 2018 Dec;13(6):735-743. doi: 10.1007/s11523-018-0597-7.

PMID:
30353488
12.

Circulating PIWI-Interacting RNAs piR-5937 and piR-28876 Are Promising Diagnostic Biomarkers of Colon Cancer.

Vychytilova-Faltejskova P, Stitkovcova K, Radova L, Sachlova M, Kosarova Z, Slaba K, Kala Z, Svoboda M, Kiss I, Vyzula R, Cho WC, Slaby O.

Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1019-1028. doi: 10.1158/1055-9965.EPI-18-0318. Epub 2018 Jul 5.

13.

Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population.

Obermannova R, Redova-Lojova M, Vychytilova-Faltejskova P, Grell P, Cho WC, Sachlova M, Svoboda M, Vyzula R, Slaby O.

Anticancer Res. 2018 Jun;38(6):3719-3724. doi: 10.21873/anticanres.12651.

PMID:
29848733
14.

Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response.

Kovacova J, Juracek J, Poprach A, Buchler T, Kopecky J, Fiala O, Svoboda M, Slaby O.

Anticancer Res. 2018 May;38(5):2961-2965.

PMID:
29715124
15.

p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.

Coates PJ, Nenutil R, Holcakova J, Nekulova M, Podhorec J, Svoboda M, Vojtesek B.

Virchows Arch. 2018 Mar;472(3):351-359. doi: 10.1007/s00428-018-2324-2. Epub 2018 Feb 27.

PMID:
29484502
16.

Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer.

Remšík J, Fedr R, Navrátil J, Binó L, Slabáková E, Fabian P, Svoboda M, Souček K.

Br J Cancer. 2018 Mar 20;118(6):813-819. doi: 10.1038/bjc.2017.497. Epub 2018 Feb 20.

17.

Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer.

Juracek J, Peltanova B, Dolezel J, Fedorko M, Pacik D, Radova L, Vesela P, Svoboda M, Slaby O, Stanik M.

J Cell Mol Med. 2018 Mar;22(3):2033-2038. doi: 10.1111/jcmm.13487. Epub 2018 Jan 24.

18.

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.

Lakomy R, Poprach A, Bortlicek Z, Melichar B, Chloupkova R, Vyzula R, Zemanova M, Kopeckova K, Svoboda M, Slaby O, Kiss I, Studentova H, Juracek J, Fiala O, Kopecky J, Finek J, Dusek L, Hejduk K, Buchler T.

BMC Cancer. 2017 Dec 21;17(1):880. doi: 10.1186/s12885-017-3901-5.

19.

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9.

Vychytilova-Faltejskova P, Merhautova J, Machackova T, Gutierrez-Garcia I, Garcia-Solano J, Radova L, Brchnelova D, Slaba K, Svoboda M, Halamkova J, Demlova R, Kiss I, Vyzula R, Conesa-Zamora P, Slaby O.

Oncogenesis. 2017 Dec 4;6(11):399. doi: 10.1038/s41389-017-0006-6.

20.

BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.

Paculová H, Kramara J, Šimečková Š, Fedr R, Souček K, Hylse O, Paruch K, Svoboda M, Mistrík M, Kohoutek J.

Tumour Biol. 2017 Oct;39(10):1010428317727479. doi: 10.1177/1010428317727479.

PMID:
29025359

Supplemental Content

Loading ...
Support Center